Nonproliferative epithelial alteration and expression of estrogen receptor and Ki67 in the contralateral breast of women treated with tamoxifen for breast cancer

Breast

Volumn 16, Issue 2, 2007, Pages 197-203

  de Souza Sales Jr , José Fernando ^a   Cabello, César ^a   Alvarenga, Marcelo ^a   Zocchio Torresan, Renato ^a   Mendes Duarte, Giuliano ^a  

^a Department of Obstetrics and Gynecology School of Medicine Universida de Estadual de Campinas   (Brazil)

Author keywords

Breast cancer; Contralateral breast; Estrogen receptor; Ki67; Tamoxifen

Indexed keywords

ESTROGEN RECEPTOR; KI 67 ANTIGEN; TAMOXIFEN CITRATE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST BIOPSY; BREAST CANCER; BREAST EPITHELIUM; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CONTROLLED STUDY; EPITHELIUM HYPERPLASIA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAMMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT DURATION; WOMEN'S HEALTH;

EID: 33947635122     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2006.10.005     Document Type: Article

References (24)

1. Fisher B., Constantino J.P., and Redmond C. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320 (1989) 479-483
2. Fisher B., Dignan J., Bryant J., et al. Five versus more than five years of tamoxifen therapy of breast cancer patients with negative lymph node and estrogen-receptor-positive tumors. J Natl Cancer Inst (1996) 1529-1542
3. Brisson J., Brisson B., Cote G., et al. Tamoxifen and mammographic breast densities. Cancer Epidemiol Biomarkers Prev 9 (2000) 911-915
4. Chow C.K., Venzon D., Jones E.C., et al. Effects of tamoxifen on mammographic density. Cancer Epidemiol Biomarkers Prev 9 (2000) 917-921
5. Veronesi U., Maisonneuve P., Costa A., et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomized trial among hysterectomized women. Lancet 362 (1998) 93-97
6. Powles T., Eeles R., Ashley S., et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial. Lancet 352 (1998) 98-101
7. Cuzick J., Forbes J., Edwards R., et al. First results of International Breast Cancer Intervention Study (IBIS I): a randomized prevention trial. Lancet 360 (2002) 817-824
8. Fisher B., Constantino J.P., Wickerham D.L., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90 18 (1998) 1371-1388
9. Dupont W.D., and Page D.L. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 312 (1985) 146-151
10. Giri D., Dundas S., Nottingham J., et al. Oestrogen receptors in benign epithelial lesion and intraduct carcinomas of the breast: an immunohistological study. Histopathology 15 (1989) 575-584
11. Kinsinger L.S., Harris R., Woolf S.H., Sox H.C., and Lohr K.N. Chemoprevention of breast cancer: a summary of the evidence for the US Preventive Services Task Force. Ann Intern Med 137 (2002) 59-69
12. Tan-Chiu E., Wang J., Constantino J.P., et al. Effects of tamoxifen on benign breast disease in women at high risk for breast cancer. J Nat Cancer Inst 95 (2003) 302-307
13. Mohsin S.K., Allred D.C., Osborne C.K., et al. Morphologic and immunophenotypic markers as surrogate endpoints of tamoxifen effect for prevention of breast cancer. Breast Cancer Res Treat 94 (2005) 205-211
14. Walker K.J., Price-Thomas J.M., Candlish W., and Nicholson R.I. Influence of the antiestrogen tamoxifen on normal breast tissue. Br J Cancer 64 (1991) 764-768
15. Bernardes J.R.M., Nonogaki S., Seixas M.T., Rodrigues de Lima G., Baracat E.C., and Gebrin L.H. Effect of a half dose of tamoxifen in normal tissue. Int J Gynecol Obstet 67 (1999) 33-38
16. Facina G., Baracat E.C., Lima G.R., and Gebrin L.H. Efeitos de diferentes doses de tamoxifeno sobre a proliferação celular do epitélio mamário. RBGO 25 (2003) 185-191
17. Hofseth L.J., Raafat A.M., Osuch J.R., Pathak D.R., Slomsky C.A., and Haslam S.Z. Hormone replacement therapy with estrogen or estrogen plus metroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 84 (1999) 4559-4565
18. Jacquemier J.D., Hassoun J., Torrente M., and Martin P.M. Distribution of estrogen and progesterone receptor in healthy tissue adjacent to breast lesions at various stages-immunohistochemical study of 107 cases. Breast Cancer Res Treat 15 (1990) 109-117
19. Lawson J.S., Field A.S., Tran D.D., Killen J., Mascarenic G., Ishikura H., et al. Breast cancer incidence at estrogen receptor alpha in normal mammary tissue-an epidemiologic study among Japanese women in Japan and Hawaii. Int J Cancer 95 (2002) 685-687
20. Elledge R.M., and Fuqua S.A.W. Oestrogen and progesterone receptors. In: Harris J.R., Lippiman M.E., Morrow M., and Osborne C.K. (Eds). Diseases of the breast (2000), Lippincott Williams & Wilkins, Massachusetts
21. Sughayer M.A., Al-Khawaja M.M., Massarweh S., and Al-Masri M. Prevalence of hormone receptors and her2/neu in breast cancer cases in Jordan. Pathol Oncol Res 12 (2006) 83-86
22. Rao A.V., Mohammed W.A., Ragoonanan C., and Omo-Igbinomwanhia N.E. Evaluation of oestrogen and progesterone receptors, and c-erbB-2 in carcinoma of the breast in Trinidadian women. West Indian Med J 51 (2002) 4-9
23. Wolf N.J. Breast patterns as index of risk of development breast cancer. Am J Roentgenol 126 (1976) 11309
24. Howell A., Cuzick J., Baum M., et al. ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 (2005) 60-62